Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Mother and Infant Visit Adherence and Treatment Engagement Study (MOTIVATE!)

22. April 2021 aktualisiert von: University of Colorado, Denver

Maximizing Adherence and Retention for Women and Infants in the Context of Option B+

This is a 2x2 factorial cluster randomized trial of two interventions to improve retention and adherence for women and infants on Option B+. The overall goal is to determine which intervention (or combination of interventions) maximizes antiretroviral therapy (ART) adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes.The proposed study will be conducted in rural Nyanza Province, Kenya at 20 low-resource primary health care facilities and associated communities supported by Family AIDS Care and Education Services (FACES), a President's Emergency Plan for AIDS Relief (PEPFAR)-funded HIV prevention care, and treatment program, ((AIDS) acquired immune deficiency syndrome, (HIV) human immunodeficiency virus) . The investigators will assess both process and outcome indicators using a 2x2 factorial design, in which equal numbers of clusters will be randomized to one of the interventions (community-based mentor mothers or theory-based mobile text messages), both interventions, or standard of care. The interventions will be added to fully integrated high quality HIV and antenatal, maternal, neonatal, and child health (ANC/MNCH) services already offered at these sites.

Studienübersicht

Status

Abgeschlossen

Detaillierte Beschreibung

In order to eliminate new pediatric HIV infections, save maternal lives, and simplify antiretroviral therapy (ART) implementation in settings with generalized HIV epidemics, current World Health Organization (WHO) guidance recommends lifelong triple ART for all pregnant and breastfeeding women (Option B+). However, despite the promise of Option B+ to remove logistical barriers and to promote maternal health through life-long ART, this strategy brings challenges. Key amongst these challenges are adherence to ART and continuous retention in HIV care, especially for women who do not require ART for their own health. Barriers to adherence and retention in care for prevention of mother-to-child transmission (PMTCT) have been identified at the individual, interpersonal, community, and health facility levels; yet specific barriers in the context of Option B+ are not well understood. The investigators' study will be conducted at 20 health facilities and associated communities in Nyanza Province, Kenya where Mother to Child Transmission (MTCT) rates prior to Option B+ roll-out remained near 10%, despite the wide availability of PMTCT services. As Option B+ is scaled up in Kenya, it is essential to identify effective methods to ensure long-term adherence and retention in care for mother-baby pairs, throughout pregnancy, breastfeeding, and beyond. Building on the investigating team's prior research experience in this setting, the investigators propose to gain understanding of and address potential barriers at the individual, community, and health facility levels through formative research with HIV-positive pregnant and postpartum women, their male partners, and health care providers. This information will be used to refine two proposed interventions that are highly likely to maximize ART adherence and retention in care among HIV-infected pregnant women and HIV-exposed infants. These interventions will be rigorously tested in rural Kenya, using a cluster randomized 2x2 factorial design. The evidence-based interventions to be tested will include 1) community Mentor Mothers (cMM) who will provide support for ART adherence and retention in care for HIV-positive women in the community and 2) individually tailored, theory based mobile phone text messages to help retain women and infants in HIV care. The investigators' overall goal is to determine which intervention (or combination of interventions) maximizes ART adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes. The investigators' primary outcomes will include ART adherence at 12 months postpartum and retention in care, measured by a documented HIV care visit within 90 days prior to 12 months postpartum. Secondary outcomes will include MTCT at 6 weeks, 12 months and 18 months; as well as maternal viral loads and CD4 counts. Results from this study will inform the scale-up of Option B+ in Kenya by identifying effective interventions and combinations of interventions that can reduce barriers and increase facilitators of optimal ART adherence and retention in care with the aims of reaching the elimination of mother to child transmission of HIV and significantly improving maternal health.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

1338

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Nairobi, Kenia
        • Kenya Medical Research Institute

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • Age 18 years or older,
  • HIV-infected pregnant women and their HIV-exposed infants pairs,
  • attends the antenatal care (ANC) clinic at one of the study sites.

Exclusion Criteria:

  • Less than 18 years of age,
  • HIV-infected women not currently pregnant,
  • not HIV-infected at the time of the first ANC visit.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Fakultätszuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Sonstiges: cMM and Text Messaging
Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention. The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
Home visits from community mentor mothers
Text messages received on mobile phone
Sonstiges: cMM Only
Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
Home visits from community mentor mothers
Sonstiges: Text Messaging Only
Participants randomized to this arm will receive the mobile phone text messaging intervention only. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
Text messages received on mobile phone
Kein Eingriff: Neither cMM nor Text Messaging
Participants randomized to this arm will receive standard of care with no interventions.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Self-reported adherence on antiretroviral therapy
Zeitfenster: 12 months post-partum
Self-report
12 months post-partum
Adherence on antiretroviral therapy
Zeitfenster: 12 months post-partum
Viral load<100 copies/ml based on medical records
12 months post-partum
Adherence on antiretroviral therapy (infant)
Zeitfenster: 12 months post-partum
Use of ARVs for the infant
12 months post-partum
Retention in care
Zeitfenster: 12 months post-partum
Proportion of women who have an HIV care visit within 90 days at 12 months after the birth
12 months post-partum
Adherence on antiretroviral therapy (dried blood spots)
Zeitfenster: 12 months post-partum
Viral load<100 copies/ml based on dried blood spots
12 months post-partum

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Maternal CD4 count change
Zeitfenster: 6 months after baseline
Change in CD4 count baseline to 6 months after baseline
6 months after baseline
Maternal viral load count change
Zeitfenster: 6 months after baseline
Change in viral load from baseline to 6 months after baseline
6 months after baseline
Infant retention in care (feeding method)
Zeitfenster: 12 and 18 months
Infant feeding method
12 and 18 months
Infant retention in care
Zeitfenster: 12 and 18 months
Retention in care through 12 and 18 months
12 and 18 months
Infant retention in care (survival status)
Zeitfenster: 12 and 18 months
Survival status of infant
12 and 18 months
Uptake of intervention services (Number/types of text messages sent)
Zeitfenster: 3 years
Number/types of text messages sent
3 years
Uptake of intervention services (receipt of text messages)
Zeitfenster: 3 years
Receipt of text messages
3 years
Uptake of intervention services (home visits)
Zeitfenster: 3 years
Number of home visits received
3 years
Uptake of intervention services (support groups attended)
Zeitfenster: 3 years
Number of support groups attended.
3 years
Mother-to-Child-Transmission
Zeitfenster: 6 weeks, 9 months and 18 months
Result of infant HIV test at 6 wks, 9,18 months
6 weeks, 9 months and 18 months
Infant testing
Zeitfenster: 6 weeks, 9 months and 18 months
Uptake and date of infant testing
6 weeks, 9 months and 18 months
Infant enrollment in care
Zeitfenster: 6 weeks
Infant enrollment in HIV care
6 weeks
Male partner involvement
Zeitfenster: 12 months post-partum
Composite variable including Y/N response to indicate if male partner attended a health visit with his female partner, encouraged facility delivery, reminded to take HIV medication, reminded to go for HIV care, provided transport money to go to the clinic/dispensary, reminded to give the infant prophylaxis, helped giving the infant prophylaxis medication, collected medication for the woman or infant, encouraged specific infant feeding, and encouraged pediatric HIV testing. These are assessed in the follow-up questionnaires completed at 12 months post-partum.
12 months post-partum

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Mai 2014

Primärer Abschluss (Tatsächlich)

1. April 2019

Studienabschluss (Tatsächlich)

1. März 2021

Studienanmeldedaten

Zuerst eingereicht

11. März 2015

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. Juli 2015

Zuerst gepostet (Schätzen)

7. Juli 2015

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

26. April 2021

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. April 2021

Zuletzt verifiziert

1. April 2021

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Menschlicher Immunschwächevirus

Klinische Studien zur cMM

Abonnieren